(NASDAQ: ANL) Adlai Nortye Group's forecast annual revenue growth rate of -6.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Adlai Nortye Group's revenue in 2026 is $18,056,000.On average, 7 Wall Street analysts forecast ANL's revenue for 2026 to be $3,436,724,739, with the lowest ANL revenue forecast at $2,480,222,171, and the highest ANL revenue forecast at $5,963,893,007. On average, 6 Wall Street analysts forecast ANL's revenue for 2027 to be $1,951,257,511, with the lowest ANL revenue forecast at $0, and the highest ANL revenue forecast at $6,045,034,409.
In 2028, ANL is forecast to generate $3,334,718,406 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $8,114,140,146.